Impact of antifibrotic therapy on disease progression, all-cause mortality, and risk of acute exacerbation in non-IPF fibrosing interstitial lung diseases: evidence from a meta-analysis of randomized controlled trials and prospective controlled studies.
De-Yu LiXin LiuJing-Yi HuangWen-Lu HangGu-Ran YuYong XuPublished in: Therapeutic advances in respiratory disease (2024)
This study protocol was registered with PROSPERO (registration number: CRD42023411272).
Keyphrases
- study protocol
- respiratory failure
- liver failure
- chronic obstructive pulmonary disease
- idiopathic pulmonary fibrosis
- randomized controlled trial
- systematic review
- interstitial lung disease
- clinical trial
- drug induced
- case control
- open label
- extracorporeal membrane oxygenation
- stem cells
- rheumatoid arthritis
- mesenchymal stem cells
- double blind
- intensive care unit
- bone marrow